JP2011173928A5 - - Google Patents

Download PDF

Info

Publication number
JP2011173928A5
JP2011173928A5 JP2011128592A JP2011128592A JP2011173928A5 JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5 JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
dose
epothilone
pharmaceutical formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011128592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011173928A (ja
Filing date
Publication date
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed filed Critical
Publication of JP2011173928A publication Critical patent/JP2011173928A/ja
Publication of JP2011173928A5 publication Critical patent/JP2011173928A5/ja
Pending legal-status Critical Current

Links

JP2011128592A 1998-02-25 2011-06-08 癌処置のためのエポチロンの使用 Pending JP2011173928A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB9803905.0 1998-02-25
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GB9803907.6 1998-02-25
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GB9805937.1 1998-03-19
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
GB9805936.3 1998-03-19
US09/233,993 1999-01-19
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000533117A Division JP2002504511A (ja) 1998-02-25 1999-02-23 癌処置のためのエポチロンの使用

Publications (2)

Publication Number Publication Date
JP2011173928A JP2011173928A (ja) 2011-09-08
JP2011173928A5 true JP2011173928A5 (enExample) 2012-07-26

Family

ID=27451759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011128592A Pending JP2011173928A (ja) 1998-02-25 2011-06-08 癌処置のためのエポチロンの使用

Country Status (4)

Country Link
US (1) US6302838B1 (enExample)
JP (1) JP2011173928A (enExample)
AT (1) ATE483462T1 (enExample)
DE (1) DE69942827D1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
RU2003128311A (ru) * 2001-02-20 2005-03-10 Бристол-Маерс Сквибб Компани (Us) Способ лечения резистентных опухолей с применением аналогов эпотилона
KR100848197B1 (ko) * 2001-02-27 2008-07-24 노파르티스 아게 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물
PT1372650E (pt) * 2001-03-19 2009-02-25 Novartis Ag Associações compreendendo um agente antidiarreico e uma epotilona ou um derivado de epotilona
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20070203346A1 (en) * 2001-04-30 2007-08-30 Oregon State University Method for synthesizing epothilones and epothilone analogs
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
BR0306861A (pt) * 2002-01-14 2004-11-03 Novartis Ag Combinações que compreendem epotilonas e antimetabólitos
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
KR20040106422A (ko) * 2002-05-01 2004-12-17 노파르티스 아게 간암 및 다른 암 질병 치료용 에포틸론 유도체
CN101389334A (zh) * 2002-05-20 2009-03-18 高山生物科学股份有限公司 埃坡霉素d的给药方法
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PT1506203E (pt) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
SI1553938T1 (sl) * 2002-10-15 2007-06-30 Univ Louisiana State Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
JP4939220B2 (ja) * 2003-05-15 2012-05-23 アークル インコーポレイテッド p38の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
WO2005000292A1 (en) * 2003-06-27 2005-01-06 Novartis Ag Cancer treatment with epothilones
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
EP3266867A1 (en) 2006-04-14 2018-01-10 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
CA2744713A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
CN102361631A (zh) * 2009-03-25 2012-02-22 诺瓦提斯公司 含有药物和sirna的药物组合物
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Similar Documents

Publication Publication Date Title
JP2011173928A5 (enExample)
CA2856646C (en) Combination treatment of cancer
JP2014515373A5 (enExample)
JP2009102342A5 (enExample)
JP2018513188A5 (enExample)
JP2015512406A5 (enExample)
JP2012180381A5 (enExample)
JP2020514412A5 (enExample)
JP2014526503A5 (enExample)
NZ711179A (en) Oral formulations of deferasirox
JP2012193216A5 (enExample)
JP2013541583A5 (enExample)
JP2010526101A5 (enExample)
JP2015522630A5 (enExample)
JP2017132791A (ja) 組み合わせ組成物
JP2013209384A5 (enExample)
JP2013516493A5 (enExample)
JP2016516773A5 (enExample)
JP2019218379A5 (enExample)
JP2018531605A5 (enExample)
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
JP2010538066A5 (enExample)
JP2020510043A5 (enExample)
JP2016505050A5 (enExample)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合